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Summary  Percutaneous  pulmonary  valve  implantation  now  has  a  key  role  in  the  setting  of
dysfunctional  right  ventricle-to-pulmonary  artery  conduits  or  failing  bioprosthetic  pulmonary
valves. However,  despite  the  excellent  results  obtained  with  the  two  devices  available  currently
(the Melody® valve  [Medtronic  Inc.,  Minneapolis,  MN,  USA]  and  the  Edwards  SAPIEN® valve
[Edwards Lifesciences,  Irvine,  CA,  USA]),  many  patients  eligible  for  pulmonary  valve  replace-
ment remain  unsuitable  for  percutaneous  pulmonary  valve  implantation,  mainly  because  ofMelody valve large native  outﬂow  tracts.  Accordingly,  one  of  the  major  challenges  for  the  future  is  to  expand
percutaneous  pulmonary  valve  implantation  to  a  broader  population  of  patients.  Moving  for-
ward, there  is  important  ongoing  research  that  is  intended  to  improve  patient  outcomes,  expand
percutaneous  pulmonary  valve  implantation  therapy  and  continue  to  reduce  the  number  of
open-heart  surgeries  in  this  population.  In  this  review,  we  underline  the  limitations  and  issues
Abbreviations: MRI, Magnetic resonance imaging; PPVI, Percutaneous pulmonary valve implantation; PVR, Pulmonary valve replacement;
RVOT, right ventricular outﬂow tract.
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associated  with  the  devices  available  currently,  and  we  focus  on  the  development  of  new  strate-
gies (such  as  hybrid  approaches  or  magnetic  resonance-guided  procedures),  new  devices  (such
as right  ventricular  outﬂow  tract  reducers  or  the  novel  Native  Outﬂow  Tract  valved  stent  from
Medtronic)  and  new  technologies  (such  as  tissue-engineered  valves),  which  may  help  to  take
up these  challenges  and  represent  the  future  of  transcatheter  valve  implantation.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  remplacement  valvulaire  pulmonaire  percutané  a  désormais  un  rôle  clé  dans  la
prise en  charge  des  dysfonctions  de  conduits  entre  le  ventricule  droit  et  l’artère  pulmonaire
ou de  bioprothèses  pulmonaires.  Cependant,  malgré  les  excellents  résultats  obtenus  avec  les
prothèses percutanées  actuellement  disponibles  (Melody® [Medtronic  Inc.,  Minneapolis,  MN,
États-Unis]  et  Edwards  SAPIEN® [Edwards  Lifesciences,  Irvine,  CA,  États-Unis]),  de  nombreux
patients nécessitant  un  remplacement  valvulaire  pulmonaire  ne  sont  pas  éligible  pour  cette
technique percutanée,  essentiellement  du  fait  d’une  large  voie  droite  native.  De  ce  fait,  un
des principaux  déﬁs  pour  l’avenir  est  d’étendre  l’implantation  valvulaire  percutanée  à  une  plus
large proportion  de  patients.  Il  existe  ainsi  un  important  champ  de  recherche  ayant  pour  but
d’améliorer  le  devenir  des  patients,  d’étendre  les  indications  de  cette  thérapie  et  de  continuer
de réduire  le  nombre  de  chirurgies  dans  cette  population.  Dans  cette  revue,  nous  souligneront
les principales  limites  des  dispositifs  actuels  et  nous  nous  focaliseront  sur  le  développement
de nouvelles  stratégies  (comme  les  procédures  hybrides  ou  les  procédures  guidées  par  IRM),
de nouveaux  dispositifs  (comme  les  réducteurs  de  taille  de  voie  droite  ou  la  nouvelle  prothèse
Native Outﬂow  Tract  de  Medtronic)  et  de  nouvelles  technologies  (stents  valvés  crées  par  bio-
engineering)  qui  pourraient  permettre  de  relever  ces  challenges  et  constitueront  le  futur  du
remplacement  valvulaire  pulmonaire  percutané.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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atients  with  complex  congenital  heart  defects  are  sub-
ect  to  numerous  open-heart  surgeries,  usually  performed  to
elieve  right  ventricular  outﬂow  tract  (RVOT)  abnormalities,
ith  incremental  risks  and  signiﬁcant  morbidity.  In  Septem-
er  2000,  the  ﬁrst  successful  percutaneous  pulmonary  valve
mplantation  (PPVI)  was  performed,  using  a  bovine  jugular
ein  sutured  on  a  platinum  stent  [1].  Since  this  ﬁrst-in-
an  report,  catheter-based  valve  implantation  has  evolved
apidly  over  the  last  decade.  This  novel  treatment  option
as  changed  the  culture  of  paediatric  cardiology,  adult
ardiology  and  cardiovascular  surgery.  Moreover,  it  has
odiﬁed  the  way  in  which  the  expectant  family  of  a foe-
us  likely  to  undergo  several  RVOT  surgeries  is  counselled
2].
Currently,  there  are  two  devices  used  for  PPVI:  the
elody® valve  (Medtronic  Inc.,  Minneapolis,  MN,  USA),  a
ovine  jugular  vein  valve  sutured  within  a  platinum  and
ridium  stent;  and  the  Edwards  SAPIEN® valve  (Edwards
ifesciences,  Irvine,  CA,  USA),  made  of  bovine  pericardium
ounted  in  a  rigid  stainless  steel  stent,  although  the  SAPIEN
alve  is  not  widely  available.  Multiple  studies  have  demon-
trated  that  PPVI  with  the  Melody  valve  is  safe  and  effective,
ith  a  high  rate  of  procedural  success,  and  durable  in  short-
nd  medium-term  follow-up  in  properly  selected  patients
3,4].  The  SAPIEN  transcatheter  heart  valve  is  an  alterna-
ive  device  with  similar  safety  and  efﬁcacy  in  limited  studies
5,6].  PPVI  with  these  revolutionary  devices  provides  a  non-
urgical  alternative  in  the  treatment  of  dysfunctional  RVOT
2
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fnd  allows  a  reduction  in  the  number  of  open-heart  surgeries
n  these  patients.
However,  despite  these  excellent  results,  the  het-
rogeneity  of  this  population  and  the  wide  variety  of
mplantation  site  morphologies,  sizes  and  dynamics,  lim-
ts  the  suitability  of  PPVI  to  approximately  15%  of  patients
ho  require  pulmonary  valve  replacement  (PVR),  indicat-
ng  surgical  PVR  in  85%  of  patients  [7].  Accordingly,  one  of
he  major  challenges  for  the  future  is  to  expand  PPVI  to  a
roader  population  of  patients,  including  those  with  large
nd/or  patched  RVOTs  or  complex  lesions  with  a  vulnerable
eighbourhood,  and  small  children.
Several  authors  have  described  advanced  techniques  or
evice  modiﬁcations  to  make  these  patients  suitable  for
he  transcatheter  technique  [8—10].  The  hybrid  approach,
ncluding  strategies  to  surgically  and/or  percutaneously
repare  the  outﬂow  tract  for  subsequent  transcatheter
alve  deployment,  is  another  key  area  of  pulmonary  valvu-
ation  development.
Furthermore,  extensive  research  and  development  is
eing  conducted  to  design  a  suitable  transcatheter  valve  for
atients  with  a  dysfunctional  native  or  patched  RVOT,  typ-
cally  with  signiﬁcant  pulmonary  regurgitation  rather  than
bstruction,  which  is  too  large  for  the  devices  available
urrently.  The  ﬁrst-in-human  implantation  of  a  large  RVOT
ranscatheter  valve  developed  by  Medtronic  was  reported  in
010  [11].
In  this  review  we  aim  to:  underline  the  limitations  and
ssues  associated  with  the  Melody  and  SAPIEN  valved  stents;
ocus  on  the  alternative  techniques  and  approaches  that
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aThe  future  of  transcatheter  pulmonary  valvulation  
allow  effective  PPVI  with  these  valves;  and  describe  the
ongoing  research  into  and  design  of  new  transcatheter  pul-
monary  devices.
Percutaneous pulmonary valve
implantation in large right ventricular
outﬂow tract
Current  transcatheter  pulmonary  valves  have  demonstrated
a  high  rate  of  procedural  success  with  acceptable  safety  pro-
ﬁles  and  favourable  outcomes.  However,  of  the  patients  with
a  clinical  indication  for  PVR,  only  15%  can  be  treated  with
the  devices  available  currently,  indicating  surgical  PVR  in
85%  of  patients,  as  they  have  a  history  of  transannular  patch
reconstruction  of  the  RVOT,  leading  to  distortion  and  dilation
of  that  region  and  precluding  PPVI  because  of  the  absence
of  an  appropriate  landing  zone  (16—24  mm  for  the  Melody
valve;  21—27  mm  for  the  SAPIEN  valve)  [7,12,13].
To  extend  PPVI  indications,  some  authors  started  to  pro-
pose  valve  implantation  in  selected  native  outﬂow  tracts
with  stenotic  and/or  non-distensible  physiology  [14]. Other
reports  described  advanced  techniques  to  make  these
patients  suitable  for  the  transcatheter  technique  (i.e.  the
use  of  two  Melody  valves  implanted  in  respective  pulmonary
arteries  in  a  single  patient;  jailing  and/or  Russian  doll  tech-
niques)  [9,15—17].  Cheatham  et  al.  showed  that  PPVI  using
a  24  mm  balloon  catheter  for  the  deployment  of  the  Melody
valve  was  feasible,  without  impairment  of  valvular  function
(RVOT  diameter  of  26  mm)  [18].  The  SAPIEN  valve  diameters
are  23,  26  and  29  mm,  which  makes  it  potentially  more  suit-
able  for  PPVI  in  large-diameter  conduits  and  native  outﬂow
tracts  (up  to  27  mm)  than  the  Melody  valve,  but  the  device
is  not  widely  available.
Nevertheless,  most  patients  with  transannular  patch
repair  have  a  dilated  and  distensible  RVOT,  making  device
embolization  a  concern  in  this  population.  Accordingly,
there  is  worldwide  interest  in  developing  new  strategies
with  the  current  devices  and/or  a  new  design  of  transcat-
heter  heart  valve  to  make  these  patients  suitable  for  PPVI,
avoiding  the  risk  of  surgical  PVR.
A new transcatheter pulmonary valve
The  ﬁrst-in-human  implantation  of  a  new  self-expandable
transcatheter  pulmonary  valve  was  reported  in  2010  [11].
This  was  done  under  compassionate  use  in  a  42-year-old  man
with  pulmonary  insufﬁciency.  The  device  design  was  tested
in  animals  and  modiﬁed  to  ﬁt  the  patient’s  anatomy  and  to
allow  safe  implantation.  The  authors  did  computed  tomo-
graphy  of  the  patient’s  RVOT  to  create  prototyping  models
to  customise  and  test  the  device,  which  was  successfully
implanted  into  the  patient  with  a  satisfactory  result.  No
stent  fracture  and  only  trivial  paradevice  leak  were  observed
at  6-month  follow-up.  This  new  prosthesis  is  called  the
Native  Outﬂow  Tract  device  (Medtronic  Inc.,  Minneapolis,
MN,  USA).  Besides  the  use  of  porcine  pericardium  to  make
the  valve,  the  main  modiﬁcations  to  this  valved  stent,  com-
pared  with  the  Melody  and  SAPIEN  valves,  are  an  hourglass
geometry  (i.e.  larger  diameters  at  the  proximal  and  distal
end;  smaller  diameters  in  the  central  portion  holding  the
a
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alve)  and  the  use  of  a  self-expanding  nitinol  stent  with  a
olymeric  graft,  which  should  help  the  stability  of  the  device
n  various  RVOT  anatomies  (Fig.  1).
An  Investigational  Device  Exemption  trial  of  the
ative  Outﬂow  Tract  device  has  been  enrolling  subjects
ince  April  2013  (clinicaltrials.gov  identiﬁer:  NCT01762124;
0  patients  enrolled  so  far).  Given  the  limitations  in  the
nimal  model  regarding  conﬁrmation  of  device  boundary
onditions,  this  feasibility  study  aims  to  characterize  that
nformation  as  well  as  to  evaluate  safety,  procedural  feasi-
ility  and  performance  data,  which  will  be  used  in  the  future
evelopment  of  the  device.  This  innovative  device  may  be
he  future  of  PPVI.  However,  regarding  the  wide  anatom-
cal  variability  of  the  RVOT  and  the  frequently  associated
ulmonary  artery  disease  encountered  in  this  patient  pop-
lation,  alternative  techniques  allowing  valve  replacement
re  still  being  explored  by  investigators  [19].  Another  device
Venous  P  Valve;  Medtech,  Shenzhen,  China)  is  presently
nder  investigation;  18  patients  have  been  implanted  in
hina,  India  and  Thailand,  but  no  data  have  been  published
o  far.  A  European  study  should  start  before  the  end  of  2015.
Finally,  one  major  innovation  in  PPVI  may  be  the  devel-
pment  of  repositionable  valved  stents  and  low-proﬁle
evices.  The  Lotus  Valve  System® (Boston  Scientiﬁc  Corpora-
ion,  Natick,  MA,  USA),  a  bovine  pericardial  valve  attached
o  a  braided  nitinol  stent  used  for  transcatheter  aortic  valve
eplacement,  features  this  speciﬁc  function.  The  braided
itinol  frame  has  a  locking  system  that  allows  controlled  pre-
ise  deployment,  recapture  and  subsequent  repositioning  or
emoval,  as  necessary  [20].
VOT reducers
atients  who  underwent  surgical  repair  of  tetralogy  of  Fal-
ot  during  infancy  using  a  transannular  patch  can  have  large
ulmonary  trunks  that  often  exceed  30  mm  in  diameter,
aking  PPVI  technically  unfeasible  with  the  current  valves.
o  extend  the  indications  of  PPVI,  the  use  of  percutaneously
mplanted  RVOT  size  reducers  has  been  described.  Boud-
emline  et  al.  designed  and  developed  several  versions  of  a
reshaped  self-expandable  stent,  forming  a  covered  double
ylinder,  with  the  internal  diameter  calibrated  to  authorize
mplantation  of  available  valved  stents.  The  device  is  avail-
ble  with  various  external  diameters  (30—40  mm  ; Fig.  2).
his  device  was  implanted  in  sheep  (n  =  30)  that  had  pre-
iously  had  surgical  RVOT  enlargement.  During  the  same
rocedure,  a  valved  stent  (bovine  jugular  vein)  was  subse-
uently  deployed  in  the  central  part  of  the  ﬁller.  The  main
omplications  were  device  embolization  (n  =  1)  and  para-
rosthetic  leaks  (6/24  animals;  25%).  The  leak  was  related  to
ndersizing  of  the  device.  Indeed,  5/6  leaks  (83%)  occurred
n  animals  where  the  size  of  the  device  was  less  than  5  mm
arger  than  the  pulmonary  artery  diameter  (P  <  0.05),  which
onﬁrms  that  oversizing  the  device  is  mandatory  for  stent
nchoring  and  ultimately  for  deﬁnitive  ﬁxation  to  the  vas-
ular  wall  [21—23].
Other  authors  have  reported  on  the  development  of
 self-expandable  nitinol  stent,  inside  which  is  attached
 speciﬁcally  designed  polyester  graft  (a  central  tube,
0  mm  in  diameter,  with  two  ﬂared  extremities),  which  has
een  successfully  implanted  in  sheep  (n  =  6)  [24].  During
he  same  procedure,  a  20  mm  nitinol  valved  stent  (bovine
638  Z.  Jalal  et  al.
Figure 1. Native Outﬂow Tract transcatheter pulmonary valve device (Medtronic Inc., Minneapolis, MN, USA). A. Lateral view of the nitinol
self-expandable stent with an hourglass geometry and the valved-stent delivery system. B. Closed porcine pericardial valve leaﬂets. C. and
D. Valved stent (C) charged in the delivery system and (D) partially deployed.
Figure 2. RVOT reducer. Latest version of the RVOT reducer developed by Boudjemline et al., shown uncovered. A. and B. Front and
oblique view of the device; the extremities are directed inward and back toward an intermediate position forming a second wall in parallel
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ericardium)  was  implanted  within  the  deployed  size
educer.  These  devices  seem  very  promising,  but  they  have
ot  been  tested  for  human  application  so  far.  Indeed,  the
pplicability  of  these  devices  to  the  human  anatomy  with
alciﬁed  RVOT  or  non-circular  cross-sectional  shape  remains
o  be  proven.
ercutaneous pulmonary valve
mplantation in small children and those
ith a low body weighthe  transcatheter  valves  available  currently  (the  Melody  and
APIEN  valves)  require  a  large  delivery  sheath  (22  and  24  Fr,
espectively),  limiting  the  use  of  this  technology  in  patients
h
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eighing  >  30  kg.  A  recent  study  focused  on  PPVI  results  with
he  Melody  valve  in  this  speciﬁc  population  [25].  Twenty-ﬁve
hildren  (median  age,  8  years;  median  weight,  21.4  kg)  were
cheduled  for  PPVI  in  conduits  ranging  from  12  to  23  mm,
sing  a  standard  technique  and  devices.  Vascular  access  was
y  means  of  the  femoral  vein  (n  =  17),  the  right  internal  jugu-
ar  vein  (n  =  6)  or  the  left  subclavian  vein  (n  =  2).  PPVI  was
easible  in  all  but  two  patients  (risk  of  coronary  compression
n  one;  inability  to  advance  the  delivery  sheath  through  the
ommon  femoral  vein  in  the  other).  Post-PPVI  results  showed
ood  valve  function.  This  report  underlines  that  PPVI  is  fea-
ible  in  children  weighing  <  30  kg  with  good  procedural  and
aemodynamic  results.  However,  the  population  sample  size
nd  short  follow-up  limit  the  statistical  signiﬁcance  of  such
esults.  Furthermore,  procedural  adverse  events  were  rel-
tively  common,  although  they  had  already  been  reported
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in  the  same  proportions  in  studies  with  larger  patients  [4].
Nevertheless,  it  is  probable  that  small  patients  are  at  risk  of
some  complications  related  to  the  size  and  stiffness  of  the
delivery  system  and  vascular  access  issues.
Although  the  optimal  timing  for  intervention  in  RVOT
conduit  dysfunction  remains  unclear,  there  is  a trend
towards  earlier  intervention  in  the  paediatric  population,
to  minimize  deleterious  effects  of  conduit  failure  on  right
ventricular  function  [26,27].
As  technology  continues  to  advance,  minimizing  the
delivery  sheath  and  valve  size,  and  developing  mini-invasive
hybrid  approaches  should  be  prioritized,  so  that  this  technol-
ogy  can  be  used  in  younger  patient  populations.  New  devices
with  reduced  delivery  systems  are  under  development  at
the  moment.  The  most  advanced  device  is  based  on  a  dry
valve  mounted  on  a  stent.  The  whole  system  comes  pre-
pared,  already  mounted  in  the  delivery  system  and  in  the
same  package.  The  valve  being  dry,  the  delivery  system  is
only  14  Fr,  making  the  use  of  this  device  possible  in  small
children.
‘Think hybrid’
Hybrid procedures
Hybrid  procedures  involving  the  use  of  surgical  and  trans-
catheter  techniques  are  increasingly  common  in  the  ﬁeld
of  congenital  heart  diseases,  leading  to  optimized  efﬁcacy
and  safety  when  conducting  at-risk  procedures  [28].  Hybrid
approaches  need  a  collaborative  relationship  between  car-
diac  surgeons  and  interventionists,  especially  during  the
preprocedural  work-up  to  assess  patient  suitability  and
choose  the  appropriate  technique.  Furthermore,  while  the
advantage  of  PPVI  is  to  avoid  repeated  open-heart  surgeries,
the  ideal  hybrid  procedure  should  be  as  minimally  invasive
as  possible.
In  the  ﬁeld  of  transcatheter  PVR,  animal  and  human
hybrid  procedures  mostly  aimed  to  perform  valve  implan-
tation  in  large  RVOTs.  A  few  years  after  the  ﬁrst  PPVI,
the  Necker  Hospital  for  Sick  Children  group  (Paris,  France)
reported  off-pump  PVR  using  a  combined  approach  in
ewes.  A  left  thoracotomy  was  ﬁrst  performed,  then  the
main  pulmonary  artery  was  banded  using  two  radiopaque
rings  of  nitinol,  giving  a  reduction  in  RVOT  diameter  from
30  to  17.6  mm.  Subsequent  PVR  through  a  percutaneous
or  transventricular  approach  was  then  performed  without
extracorporeal  circulation,  using  an  18-mm  bovine  jugu-
lar  venous  valve  mounted  in  a  balloon-expandable  stent
[29].  In  line  with  these  trials  on  valve  implantation  into  the
pulmonary  position,  ﬁrst  results  described  modiﬁed  valve
delivery  into  the  aortic  or  mitral  position  [30].
Furthermore,  Schreiber  et  al.  published  another
approach,  which  allows  implantation  of  a  Shelhigh  valve
(Shelhigh  inject,  Shelhigh  Inc.,  Union,  NJ,  USA)  —  a  porcine
pulmonic  valve  mounted  inside  a  self-expandable  stent
covered  with  porcine  pericardium,  with  a  diameter  as  long
as  31  mm  —  without  the  use  of  cardiopulmonary  bypass,  in
6  patients  operated  on  with  a  transannular  patch  [31].  The
valve  was  introduced  just  beneath  the  RVOT.  One  patient
exhibited  paravalvular  leakage  and  the  valve  was  replaced
by  a  homograft  2  days  later.  After  6—12  months’  follow-up,
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he  remaining  patients  had  good  valvular  function.  However,
his  approach  requires  complete  dissection  of  the  heart
fter  full  sternotomy.
Dittrich  et  al.  published  a  report  on  an  8-year-old  boy
n  whom  transverse  mini-thoracotomy  through  the  third
ntercostal  space  was  used  to  implant  an  injectable  29  mm
tented  porcine  valve  directly  into  the  pulmonary  artery
ifurcation  [32].  The  procedure  was  performed  during  rapid
entricular  pacing  and  right  ventricular  unload  by  a  short
unning  femorally  implanted  cardiopulmonary  bypass.
More  recently,  some  authors  have  reported  an  interest-
ng  subxyphoid  hybrid  approach  as  a ﬁrst-line  method  for
mplanting  a  Melody  valve  in  a  3-year-old  boy  (12  kg),  in
hom  venous  access  using  the  Ensemble® 22  Fr  delivery  sys-
em  (Medtronic  Inc.,  Minneapolis,  MN,  USA)  was  not  feasible
33]. PPVI  was  uneventful,  with  excellent  valve  function  on
chocardiography,  and  the  patient  was  discharged  2  days
fter  the  procedure.  Other  authors  have  reported  the  use
f  perventricular  pulmonary  valve  implantations,  but  only  in
he  setting  of  complications  with  the  transfemoral  approach
n  adults  or  larger  children  [34,35].  One  concern  is  the  cre-
tion  by  this  perventricular  approach  of  a  right  ventricular
car,  which  might  lead  to  an  increased  incidence  of  ven-
ricular  arrhythmias  by  the  creation  of  re-entry  circuits,
specially  in  tetralogy  of  Fallot  patients  [36].  Despite  these
imitations,  hybrid  procedure  results  are  very  encouraging
nd  this  approach  may  be  used  increasingly  for  PVR,  whether
n  small  children  or  in  patients  with  large  RVOTs.
nticipating percutaneous pulmonary valve
mplantation during ﬁrst surgery
nother  collaborative  approach  between  surgeons  and  inter-
entionists  is  the  adjustment  of  the  surgical  strategy  to
urther  facilitate  PPVI.  By  providing  an  anatomical  substrate
or  PPVI  during  the  ﬁrst  or  second  operation,  the  surgeons
ay  minimize  the  number  of  subsequent  open-heart  pro-
edures.  In  tetralogy  of  Fallot,  the  use  of  pulmonary  valve
paring  techniques  (i.e.  recycling  the  pulmonary  valve  or
he  V-PLASTY  technique)  should  be  encouraged,  not  only  to
revent  RVOT  enlargement  and  pulmonary  insufﬁciency,  but
lso  to  allow  subsequent  PPVI  if/when  necessary  [37,38].
he  placement  of  a  GORE-TEX® band  (W.L.  Gore  &  Asso-
iates,  Newark,  DE,  USA)  on  the  main  pulmonary  artery
o  avoid  major  enlargement  is  another  strategy  to  con-
ider.  Furthermore,  surgeons  should  consider  the  possibility
f  PPVI  when  choosing  the  size  of  a  bioprosthetic  valve  or
onduit  for  PVR.  Finally,  in  case  of  early  catheterization  pro-
edures  in  operated  children,  the  placement  of  a  stent  in
he  RVOT  may  be  used  to  ﬁx  the  size  of  the  outﬂow  tract  for
ubsequent  PPVI.
urability of devices
ong-term  durability  of  PPVI  devices  has  not  been  evaluated
o  far.  Indeed,  recent  reports  have  only  described  medium-
erm  outcomes  with  these  valves  [3,4]. To  date,  no  authors
ave  compared  the  long-term  durability  of  PPVI  devices  with
urgical  valves.  However,  considering  its  behaviour  under
igh-pressure  conditions,  the  Melody  valve  seems  to  be  more
urable  than  initially  expected  [39].
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Failure  of  analogous  surgically  implanted  bioprosthetic
alves  occurs  secondary  to  deposition  of  calcium,  leading
o  progressive  dysfunction  of  the  valve.  Furthermore,  it
s  known  that  homografts  induce  a  humoral  immunologi-
al  response,  which  has  been  correlated  with  the  risk  of
ailure  [40,41].  The  use  of  tissue-engineering  valved  stents
ay  overcome  these  current  limitations.  Indeed,  tissue-
ngineered  heart  valves  require  no  anticoagulation  and
ave  the  ability  to  grow  and  remodel  without  immunologi-
al  reaction.  Tissue-engineered  valves  with  autologous  cells
ave  already  been  used  clinically  [42].  In  this  human  study,
he  authors  isolated  cells  from  children’s  peripheral  blood,
eeded  those  cells  on  a  decellularized  human  pulmonary
alve  (acellular  allograft  matrix),  placed  it  into  a  bioreactor
nd  surgically  implanted  the  new  tissue-engineered  valve
nto  the  children.  In  the  following  3.5  years,  the  pulmonary
alve  annulus  diameter  increased  and  the  valve  regurgita-
ion  decreased  slightly;  no  signs  of  valve  degeneration  have
een  observed  so  far.
More  recently,  Metzner  et  al.  implanted  percuta-
eously  similar  bioengineered  valves  sutured  on  a  nitinol
elf-expanding  stent  in  sheep  pulmonary  valves.  Gross
orphology  conﬁrmed  excellent  opening  and  closure
haracteristics  of  all  leaﬂets  after  4  weeks,  although  a  mam-
ogram  of  the  stent  showed  mild  annular  calciﬁcation
n  =  4/7)  [43].  One  limitation  of  this  method  is  the  absence  of
alved  stent  growth  ability,  although  the  use  of  biodegrad-
ble  stents  might  solve  that  issue.
Thin-ﬁlm  nitinol  has  favourable  biological  properties  as
ell  as  elastic  properties,  which  make  it  an  ideal  mate-
ial  for  use  in  transcatheter  heart  valves.  Because  nitinol
lso  has  shape  memory,  complete  heart  valves  (the  leaﬂets
nd  support  structure)  can  be  made  entirely  from  this  mate-
ial.  A  thin-ﬁlm  nitinol  heart  valve  could  be  the  ideal  hybrid
alve:  it  could  have  the  biological  compatibility  and  non-
hrombogenicity  of  tissue  valves,  and  the  longevity  of  a
echanical  valve  (nitinol  has  very  impressive  fatigue  prop-
rties).
A  semilunar  thin-ﬁlm  nitinol  heart  valve  has  been
esigned  and  tested  in  animals.  This  eNitinol  mem-
rane  —  PercValve® (Advanced  Bioprosthetic  Surfaces,  Ltd.,
an  Antonio,  TX,  USA)  —  has  leaﬂets  made  from  10  m  mem-
ranes  of  thin-ﬁlm  nitinol,  which  is  made  to  be  very  ﬂexible
y  incorporation  of  multiple  regularly-spaced  small  fenes-
rations.  It  is  a  self-expandable  valve  that  can  collapse  into
 10-Fr  sheath.  These  valves  could  have  very  unique  advan-
ages  for  improving  valve  durability,  as  they  endothelialize
apidly  and  could  certainly  be  made  to  be  sufﬁciently  low
roﬁle  for  use  even  in  small  infants  [44].
on-invasive imaging contribution
PVI  suffers  from  radiation  exposure  and  limited  visual-
zation  in  some  complex  anatomies.  In  contrast,  magnetic
esonance  imaging  (MRI)-guided  cardiac  catheterizations
nvolve  no  exposure  to  radiation  and  provide  useful  addi-
ional  information  regarding  intracardiac  and  vascular
natomy.  Various  catheter-based  interventions  frequently
sed  in  the  ﬁeld  of  congenital  heart  diseases  were  previously
erformed  in  animal  studies  using  MRI  guidance  [45,46].Z.  Jalal  et  al.
In  2010,  Tzifa  et  al.  reported  the  ﬁrst-in-man  solely
RI-guided  pulmonary  valvuloplasty  [47]. Cardiovascular
RI  characteristics  of  both  transcatheter  heart  valves  cur-
ently  commercially  available  for  transcatheter  aortic  valve
mplantation  (SAPIEN;  CoreValve® [Medtronic  Inc.,  Min-
eapolis,  MN,  USA])  were  assessed  in  vitro  [48].
Clinical  translation  for  PPVI  would  require  further  devel-
pment  of  the  devices  to  enhance  procedure  safety.
owever,  MRI-guided  PPVI  seems  promising  because  of  the
ack  of  radiation  and  additional  data  provided  for  soft  tissue
haracterization.
onclusion
PVI  has  emerged  as  a  safe  and  effective  procedure  for  the
reatment  of  RVOT  dysfunction.  Despite  the  dramatic  mod-
ﬁcations  in  the  management  of  patients  with  dysfunctional
VOT  induced  by  this  technology,  there  are  some  issues  that
ontinue  to  limit  its  indications  and  some  unanswered  ques-
ions  regarding  its  long-term  outcome.  The  development
f  new  PPVI  strategies  (such  as  hybrid  approaches  or  MRI-
uided  procedures),  new  devices  (such  as  RVOT  reducers  or
he  novel  Native  Outﬂow  Tract  device  from  Medtronic)  and
ew  technologies  (such  as  tissue-engineered  valved  stents)
ay  help  to  take  up  these  challenges  and  represent  the
uture  of  transcatheter  pulmonary  valve  implantation.
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